AusperBio Announces First Patient Dosed in Clinical Study of Investigational HBV Candidate AHB-171

Trial StartAHB-171Positive

AI Analysis

Summary

AusperBio Therapeutics announced the first patient dosed in a clinical study of AHB-171, an investigational oligonucleotide therapeutic for chronic hepatitis B treatment.

Clinical Trial Data

Outcome Details

First patient dosed in clinical study

Importance:5/10

Sentiment:

0.30

oligonucleotide therapeuticshepatitis Bclinical trialfirst patient dosed

Related Companies

$TRAX

Read the original article

Published by PR Newswire Pharma on August 3, 2026 9:30 AM

Read Original